Washington DC [US], December 9 (ANI): The US Food and Drug Administration approved two gene therapies for the treatment of sickle cell disease (SCD) in patients aged 12 years and above. Casgevy, a cell-based gene therapy, is approved for the treatment of sickle cell disease in patients 12 years of age and older with recurrent vaso-occlusive crises, the FDA announced in a statement. Casgevy is the first FDA-approved therapy utilising CRISPR/Cas9, a type of genome editing technology. Lyfgenia is a cell-based gene therapy that uses a lentiviral vector for genetic modification and is approved for …